Setting a new standard for the treatment of chronic inflammation. Press Releases Catch up on the latest news from Evommune. May 28, 2025 Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria Demonstrating Robust Activity and Favorable Safety Profile April 15, 2025 Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria March 17, 2025 Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic Dermatitis December 4, 2024 Evommune Presents Positive Clinical Results of its MRGPRX2 Antagonist (EVO756) at the 7th GA²LEN Global Urticaria Forum October 31, 2024 Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases September 3, 2024 Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria July 16, 2024 Evommune Announces Positive Proof-of-Concept Clinical Trial Results for its MRGPRX2 Antagonist (EVO756) June 24, 2024 Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio March 20, 2024 Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 in Greater China and Key Asian Countries January 18, 2024 Evommune Announces Initation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria 123 We have a range of chronic inflammatory disease programs currently in development. See Our Pipeline
